Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20444571rdf:typepubmed:Citationlld:pubmed
pubmed-article:20444571lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:20444571lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:20444571lifeskim:mentionsumls-concept:C0205276lld:lifeskim
pubmed-article:20444571lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:20444571lifeskim:mentionsumls-concept:C0600558lld:lifeskim
pubmed-article:20444571lifeskim:mentionsumls-concept:C0917927lld:lifeskim
pubmed-article:20444571pubmed:issue6lld:pubmed
pubmed-article:20444571pubmed:dateCreated2010-6-14lld:pubmed
pubmed-article:20444571pubmed:abstractTextOne of the benefits of neoadjuvant chemotherapy (NAC) is its ability to convert patients ineligible for breast conservative treatment (BCT) to be candidates for this treatment, although questions have been raised regarding the effectiveness of BCT in terms of loco-regional recurrence (LRR). The objective of this study is to evaluate LRR in this group and the influence of tumor characteristics in recurrence.lld:pubmed
pubmed-article:20444571pubmed:languageenglld:pubmed
pubmed-article:20444571pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20444571pubmed:citationSubsetIMlld:pubmed
pubmed-article:20444571pubmed:statusMEDLINElld:pubmed
pubmed-article:20444571pubmed:monthJunlld:pubmed
pubmed-article:20444571pubmed:issn1532-2157lld:pubmed
pubmed-article:20444571pubmed:authorpubmed-author:XercavinsJJlld:pubmed
pubmed-article:20444571pubmed:authorpubmed-author:DeuJJlld:pubmed
pubmed-article:20444571pubmed:authorpubmed-author:CebrecosIIlld:pubmed
pubmed-article:20444571pubmed:authorpubmed-author:RubinI SISlld:pubmed
pubmed-article:20444571pubmed:authorpubmed-author:CórdobaOOlld:pubmed
pubmed-article:20444571pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20444571pubmed:volume36lld:pubmed
pubmed-article:20444571pubmed:ownerNLMlld:pubmed
pubmed-article:20444571pubmed:authorsCompleteYlld:pubmed
pubmed-article:20444571pubmed:pagination528-34lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:meshHeadingpubmed-meshheading:20444571...lld:pubmed
pubmed-article:20444571pubmed:year2010lld:pubmed
pubmed-article:20444571pubmed:articleTitleCan we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy?lld:pubmed
pubmed-article:20444571pubmed:affiliationBreast Surgical Unit, Department of Gynaecology, Hospital Universitario Vall d'Hebron, Passeig Vall d'Hebron 119, 08035 Barcelona, Spain.lld:pubmed
pubmed-article:20444571pubmed:publicationTypeJournal Articlelld:pubmed